

COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except for share and per share amounts)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2019	2018	2019	2018
	Unaudited	Unaudited	Unaudited	Unaudited
Revenues	-	7,800	-	17,800
Cost of revenues	-	684	-	1,034
Gross profit	<u>-</u>	<u>7,116</u>	<u>-</u>	<u>16,766</u>
Operating expenses				
Research and development expenses	4,297	7,759	15,502	22,854
Marketing and business development expenses	104	692	492	1,389
General and administrative expenses	2,264	1,997	6,192	6,074
Total operating expenses	<u>6,665</u>	<u>10,448</u>	<u>22,186</u>	<u>30,317</u>
Operating loss	(6,665)	(3,332)	(22,186)	(13,551)
Financial and other income, net	174	221	588	351
Loss before taxes on income	<u>(6,491)</u>	<u>(3,111)</u>	<u>(21,598)</u>	<u>(13,200)</u>
Taxes on income	-	-	722	-
Net loss	<u>(6,491)</u>	<u>(3,111)</u>	<u>(20,876)</u>	<u>(13,200)</u>
Basic and diluted net loss per ordinary share	(0.10)	(0.05)	(0.34)	(0.25)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	65,405,851	57,207,077	62,300,582	53,855,582

COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)

	<u>September 30,</u> <u>2019</u> <u>Unaudited</u>	<u>December 31,</u> <u>2018</u>
ASSETS		
Current assets		
Cash, cash equivalents, short-term bank deposits and restricted cash	47,638	45,675
Other accounts receivable and prepaid expenses	715	903
Total current assets	<u>48,353</u>	<u>46,578</u>
Non-current assets		
Long-term prepaid expenses	700	776
Severance pay fund	2,398	2,454
Operating lease right to use Asset	3,400	-
Property and equipment, net	2,478	3,372
Total non-current assets	<u>8,976</u>	<u>6,602</u>
Total assets	<u><u>57,329</u></u>	<u><u>53,180</u></u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Other account payables, accrued expenses and trade payables	5,200	8,900
Current maturity of operating lease liability	629	-
Short-term deferred participation in R&D expenses	898	1,089
Total current liabilities	<u>6,727</u>	<u>9,989</u>
Non-current liabilities		
Long-term deferred participation in R&D expenses	2,752	3,003
Long-term operating lease liability	3,092	-
Accrued severance pay	2,894	2,945
Total non-current liabilities	<u>8,738</u>	<u>5,948</u>
Total shareholders' equity	<u>41,864</u>	<u>37,243</u>
Total liabilities and shareholders' equity	<u><u>57,329</u></u>	<u><u>53,180</u></u>